Pharmacological targeting of nAChR may reduce cognitive deficits following TBI (Verbois et al., 2003); however, α7 nAChR knockout mice do not exhibit differences in posttraumatic tissue loss or neuroinflammation (Kelso et al., 2006). This evidence concerns the gene CHRNA4 and Cognitive impairment.